Andreadis Elected Fellow of AIChE – UB Now: News and Views for UB Faculty and Staff

Stelios Andreadis, SUNY Professor Emeritus of Chemical and Biological Engineering, has been elected a Fellow of the American Institute of Chemical Engineers (AIChE) in recognition of his contributions to the field of biotechnology and bioengineering, and in particular bioengineering. tissue engineering and regenerative medicine

Fellow is the AIChE’s highest membership grade. The honor reaffirms the high regard with which colleagues and peers regard an individual’s distinctive professional accomplishments and accomplishments.

“Stelios is widely recognized as one of the top biomedical engineering researchers within the chemical engineering community, and his recognition as a member of the AIChE is well-deserved,” says Mark Swihart, SUNY and UB Professor Emeritus and chairman of the department of chemistry and biology. Engineering. “His research is producing major advances with significant health impacts, and his leadership of the Center for Cellular, Genetic and Tissue Engineering raises the profile of our department and of bioengineering research at UB.”

Andreadis is an internationally recognized leader in the field of stem cell bioengineering, particularly the engineering and regeneration of cardiovascular, neural tissue, skeletal muscle, skin and glands. His pioneering work has led to improved sources of stem cells, new biomaterials (elastomers, hydrogels) for proteins, genes and delivery, and better understanding of molecular events to improve engineered products. tissue. More recently, his work has led to a better understanding of vascular and skeletal muscle aging and how to reverse it, shedding light on the role of the immune system in vascular endothelialization and regeneration, and leading to real-world products to replace the arteries in patients.

His research interests cover a wide spectrum, ranging from basic research to technological research and preclinical/translational research. It is highly interdisciplinary and is facilitated by collaboration with researchers at UB including the Jacobs School of Medicine and Biomedical Sciences, School of Dental Medicine, New York State Center of Excellence in Bioinformatics and Life Sciences at ‘UB and the Department of Biomedical Engineering. , as well as Roswell Park Comprehensive Cancer Center.

Andreadis co-founded Angiograft LLC to commercialize acellular vascular grafts that were developed in his laboratory as arterial replacement grafts for the treatment of cardiovascular disease.

It has an exemplary record of ongoing, peer-reviewed funding, having received over $25 million in research support from public and private sources, including the National Institutes of Health, National Science Foundation, NYSTEM, and foundations. private. He has published 140 peer-reviewed publications and conference proceedings, and delivered over 80 guest seminars. He has advised 34 doctoral students, 19 master’s students, five postdoctoral researchers and more than 50 undergraduate researchers.

He is director of UB’s Center for Cell, Gene and Tissue Engineering and was director of the Stem Cells in Regenerative Medicine (SCiRM) training program, which was funded by NYSTEM to train students in cell biology. stem cells and bioengineering, and applications of stem cells in regenerative medicine. He was also Chairman of the Department of Chemical and Biological Engineering from 2012 to 2018.

He has received numerous honors, including membership in the Biomedical Engineering Society (BMES) and the College of Fellows of the American Institute for Medical and Biological Engineering (AIMBE). He received UB’s Excellence in Graduate Student Mentoring Award in 2018, a SUNY Chancellor’s Award for Scholarship and Creative Activities in 2014, an NSF CAREER Award in 2000, and a Whitaker Foundation Young Investigator Award in 1999.

A UB faculty member since 1998, Andreadis earned his doctorate in chemical engineering from the University of Michigan. Prior to joining UB, he was a postdoctoral fellow at the Center for Engineering in Medicine at Harvard Medical School, where he worked in the areas of gene therapy, tissue engineering, and regenerative medicine.

Comments are closed.